(Q43889814)

27 November 2017

title

Characterization of plasma acylcarnitines in patients under valproate monotherapy using ESI-MS/MS. (English)

1 reference

Isabel Tavares de Almeida

27 November 2017

author

object named as

de Almeida IT

7

0 references

Margarida F.B. Silva

1 reference

ORCID Public Data File 2021

author name string

Silva MF

1

1 reference

27 November 2017

Selhorst J

2

1 reference

27 November 2017

Overmars H

3

1 reference

27 November 2017

van Gennip AH

4

1 reference

27 November 2017

Maya M

5

1 reference

27 November 2017

Wanders RJ

6

1 reference

27 November 2017

Duran M

8

1 reference

27 November 2017

publication date

1 November 2001

1 reference

27 November 2017

published in

Clinical Biochemistry

1 reference

27 November 2017

volume

34

1 reference

27 November 2017

issue

8

1 reference

27 November 2017

page(s)

635-638

1 reference

Plasma and hepatic carnitine and coenzyme A pools in a patient with fatal, valproate induced hepatotoxicity

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900272-7

Decreased serum carnitine in valproate induced Reye syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900272-7

Carnitine deficiency and hyperammonemia associated with valproic acid therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900272-7

Serum carnitine during valproic acid therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900272-7

L-carnitine replacement therapy in chronic valproate treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900272-7

Carnitine disposition before and during valproate therapy in patients with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900272-7

Impaired fatty acid oxidation in children on valproic acid and the effect of L-carnitine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900272-7

Hepatotoxic effects in a child receiving valproate and carnitine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900272-7

Valproate, carnitine metabolism, and biochemical indicators of liver function. Collaborative Group for the Study of Epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900272-7

The role of carnitine supplementation during valproic acid therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900272-7

l-Carnitine Supplementation in Childhood Epilepsy: Current Perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900272-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900272-7

Quantitative plasma acylcarnitine analysis using electrospray tandem mass spectrometry for the diagnosis of organic acidaemias and fatty acid oxidation defects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900272-7

Recent developments in the investigation of inherited metabolic disorders using cultured human cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900272-7

Valproate therapy does not deplete carnitine levels in otherwise healthy children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900272-7

Valproate induces in vitro accumulation of long-chain fatty acylcarnitines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900272-7

10.1016/S0009-9120(01)00272-7

7 January 2021

Identifiers

DOI

1 reference

27 November 2017

1 reference